Access and Evidence
Indian Court Shows Concern Over Clinical Trial Practices
The Indian Supreme Court has expressed concern over the failure of regulators to curb illegal and dangerous clinical trials said to be causing “havoc” in the country.
More Clinical Articles
Access and Evidence
Business Nonsense: Why the Pharmaceutical Industry is Crippled by a Bad Business Model and How to Fix It
With spiralling clinical trial costs, pharma companies are looking for savings. But less money spent is not necessarily money better spent.
Commercial
Cloud-Based eTMF Solutions: A New Approach to Clinical Trials Management
Clinical trials are still one of the most costly, yet strategically important, areas of any life sciences company today. And as these companies continue to expand globally and outsource more of their clinical trials operations, the process grows even more complex.
Access and Evidence
EMA Will Form Advisory Groups Over Clinical Trial Transparency
The European Medicines Agency is planning to form advisory groups to look into ongoing issues of access to clinical trial data.
Access and Evidence
We Need An International Solution for Publishing Clinical Trials
Despite several guidelines stating the need to publish all trial information, an extensive amount of negative data still remains hidden.
Access and Evidence
Unique Adaptive Trial Design Software Promises a Smoother Development of Clinical Trials
New adaptive trial design software ensures that pharmaceutical manufacturers can plan time and cost-effective clinical trials through extensive simulations.
Clinical
Measuring The Impact Of Health Social Networking
Like most web companies, at HealthUnlocked we do our best to work out what factors make patients come back to our site or not.
Clinical
Social Media And ‘Real World Data’ – A Natural Partnership
Emma has set me the task of blogging about “what real-world research does”, and crucially how patients can benefit from the pharma industry using real-world research.
Clinical
From Jibber-Jabber Hell To Outcome Heaven
In the rapidly changing world of today, companies are facing major challenges when it comes to not only R&D, technology, and global and local markets, but also the social, environmental and legal context.
Commercial
Orphan drugs: the transition to better care
A pharmaceutical industry focus on orphan drug development could lead to better treatment options for the smaller patient population.